Home » Posts tagged 'sar'

Tag Archives: sar

BHP – 2017 Dividends Increased by 177%

BHP Billiton BHP benefited in 2017 from a substantial reduction in exceptional losses which fell from $6.4b in 2016  to $842m. as the Samarco dam failure in Brazil weighed less heavily on the company. The year to the 30th June turned out to be a very strong financial year with free cash flow at $12.b., the second highest on record and net debt down by 37%. On an underlying basis, EBITDA rise by 64%, basic earnings per share by 455% and attributable profit multiplied from $1.2b to $6.7b. Having laid the foundations over the past five years to improve return on capital and grow shareholder value, the momentum will continue into 2018 with volume growth of 7% expected, as well as further productivity gains.

Accordingly shareholders receive their reward with dividends for the year increased by 177% to a total of 83 cents per share.

Wood Group (John) plc WG had a mix of both robust and weaker performances across its businesses in the 6 months to the 30th June. Total revenue declined by 11% but profit was down by 86% and basic earnings per share by 89.0%. The interim dividend is increased cautiously by 3%.

Empresario Group EMR produced a record first half performance with revenue rising by 50% at constant exchange rates and adjusted profit before tax up by 24% or 12% at constant exchange rates. The company has successfully integrated its two acquisitions into the business and see them both offering further opportunities for growth.

Sareum Holdings SAR expects that profit for the year to 30th June and cash at the bank will be ahead of market expectation.

Proactis Holdings plc PHD expects to see a 31% rise in revenue for the year to 31st July, with EBITDA up 43% and profit before tax rising from 3.1m to 5.3m

 

Quantum Pharma plc QP Revenue for the half year to the 31st July rose by 13% following a strong performance from Niche Pharmaceuticals. Adjusted EBITDA rose by 23% and statutory operating prfit by 74% whilst net debt halved to 11.9m.

Luxury villas & houses for sale in Greece  – visit;   http://www.hiddengreece.net

Quoted Micro 7 November 2016

ISDX

Mechanical and engineering services provider Fluid Systems Designs Holdings (FSD) has successfully diversified into the Energy from Waste (EfW) sector and has won work on major projects. In the year to May 2016, revenues were flat at £14.5m, while pre-tax profit increased £277,000 to £372,000. The AMP6 water investment programme has commenced so demand should start to build up but there was a small reduction in revenues from this sector. New framework agreements are being pursued.

Hellenic Capital (HECP) is changing its investment policy and name. The general meeting to gain shareholder approval will be held on 16 November. The company, whose new name will be City and Commercial Investments, will have a two pronged investment policy: UK property and African natural resources. The idea is to generate steady income from property in order to cover overheads. The company can then focus its remaining capital on seeking out resources projects.

Blockchain technology investor Coinsilium Group Ltd (COIN) has divested its 27.3% stake in TRAC Technology because it no longer meets the company’s criteria. Coinsilium will receive $100,000 – 50% in cash and 50% in 2.6 million shares at 1.6p each in AIM-quoted Kolar Gold Ltd (KGLD), which have to be held for three months. Former Coinsilium director Cameron Parry is chief executive of Kolar Gold, which has also secured a 50/50 joint venture with TRAC to launch an online gold and silver trading and storage platform for the Indian market. Kolar will invest £50,000 in the joint venture. TRAC already stores 120kg of gold and 4.3 tonnes of silver for clients in vaults in London, Geneva, Singapore and Hong Kong.

Valiant Investments (VALP) has raised another £24,000 at 0.1p a share, having recently raised £51,500 at the same share price. Valiant owns 84.7% of Flamethrower, which has acquired Compass Heading, a compass app, for $12,500. Revenues are generated from advertising and in-app sales.

Capital for Colleagues (CFCP) has invested a further £100,000 in existing investee company Anthesis Consulting Group. The investment is part of a larger share placing by Anthesis in order to finance organic and acquisitive growth.

Trading in the shares of Dana Group International Investments Ltd (DANA) has been suspended because it has not released its results for the period from January 2015 to May 2016. There have been problems preparing the accounts for 21.7%-owned investee company Bonyan International Investment. Dana intends to extend the accounting period to June 2016 to align its calendar to Bonyan. Earlier this year, Dana sold its 34.12% stake in Makkah and Madinnah Commercial Investment Company. Khaled Al-Husseini has stepped down from the Dana board, while Firas Baba, the chief operating officer of Bonyan, has become a director of Dana.

AIM

Drug developer Sareum (SAR) has enough cash to finance itself for a couple of years following the licence agreement for its Chk1 inhibitor drug candidate CCT245737 with ProNAi Therapeutics. This deal shows that the strategy to licence drug candidates when they reach the point of clinical trials can work and provide cash to finance other drug candidates. Sareum has a 27.5% interest in Chk1 with co-investment partner CRT Pioneer Fund owning the rest. This deal means that Sareum effectively has cash of £1.55m – including unspent funds in the partnership of around £300,000 – plus the $1.9m (£1.5m) share of the initial payment for the licensing deal. Sareum has already received £900,000 of the initial payment with the rest due to come through in the near future and it could receive up to $550,000 more in the next 12 months if the initial milestone is achieved. There was a £674,000 cash outflow in Sareum’s most recent financial year so this cash pile could last for some time. Sareum continues to develop its TYK2 autoimmune and cancer candidates and it could purchase interests in other potential drug candidates if it can find suitable acquisitions.

Berkeley Energia (BKY) has raised £24.1m ($30m) at 45p a share in order to finance the development of the Salamanca uranium mine, which will cost a total of $100m. The amount raised was at the upper end of the range sought by the company.

X-ray and gamma ray imaging and radiation detection technology developer Kromek Group (KMK) has won a number of new contracts in recent weeks and these underpin the expectations for a reduction in loss over the next two financial years. The latest contract is in the bone mineral densitometry market and it is worth $1.2m over two years – $300,000 in the current financial year. Prior to this there was a $1.6m contract with the US Defense Threat Reduction Agency, which is another two year contract. A loss of £3.7m is forecast for the year to April 2017and that should fall to £2.1m in 2017-18.

Franchise Brands (FRAN) has announced its first acquisition since it floated in August. It is paying £900,000 in cash and shares for Barking Mad, which provides dog sitting services, and it should be earnings enhancing in the first full year. The business was established in 2000 and it has 71 franchisees covering 75 territories. The deal has led to an upgrade of the 2017 earnings forecast from 2.03p a share to 2.27p a share.

Goldplat (GDP) produced 9,129 ounces of gold in the three months to September 2016. The loss was reduced at the Kilmapesa mine and the new plant should be installed in time to move the mine into profitability in this financial year.

Caledonia Mining Corporation (CMCL) says that this year’s profit is likely to be lower than expected, partly due to a lower grade at the Blanket gold mine in Zimbabwe. WH Ireland has reduced its 2016 earnings forecast from 25.2 cents a share to 17.8 cents a share, which is still nearly double the 2015 level. The profit has also been impacted by the movement the strength of the rand against the dollar and cost of assessing investment opportunities. Gold production is still expected to be 50,400 ounces this year, rising to 60,300 ounces in 2017 when earnings of 41.9 cents a share are forecast.

MAIN MARKET

InnovaDerma (IDP) has entered the US market with its self-tanning brand Skinny Tan. Superdrug started selling Skinny Tan in the UK last February and it has become its best selling tanning brand. Production is being moved from Australia to the UK, which should reduce transport costs by early 2017. In the year to June 2016, revenues jumped from A$1.05m to A$8.4m from seven countries even before sales in the US have started. This enabled the company, which switched from the Marche Libre to the standard list in September, to move from a loss to a pre-tax profit of A$473,000 – or A$411,000 after development costs. Net debt was A$871,000 at the end of June 2016.

OTHER MARKETS

Former AIM investment company Gate Ventures has raised £2.25m at 6p a share, which is double the share price of the last trade on Britdaq. Gate recently invested £380,000 in a fundraising by AIM-quoted Reach4Entertainment. Gate is valued at more than £100m at 3p a share despite its modest asset value.

Andrew Hore

Quoted Micro 3 October 2016

ISDX

Newbury Racecourse (NYR) reported flat interim revenues of £5.56m and a higher underlying loss because of the loss of three race days to bad weather. There was a cash outflow from operations of £1.51m. The sale of a final tranche of land to David Wilson Homes has generated a disposal profit of £20.1m but the cash has not been received yet. There is £7.56m of cash in the balance sheet but the disposal proceeds will be received as homes are sold. The current market capitalisation is £17.6m, whereas shareholders funds are £44.9m.

Chapel Down Group (CDGP) says that interim revenues were 26% higher at £4.09m with the fastest growth coming in the Curious Drinks business, although the wine operations increased revenues by 14% and still remain the core activities. Curious Drinks raised £1.74m during the period and that led to a notional gain on disposal of £467,000. The cash outflow from group operations reduced from £713,000 to £441,000.

Halal verification business DagangHalal (DGHL) reported higher revenues in the six months to June 2016 but the costs of raising £3.6m and joining ISDX helped push the company into loss. Revenues grew from MYR2.96m to MYR3.34m but MYR3.54m of flotation costs and nearly trebled overheads meant that a pre-tax profit of MYR1.18m was turned into a loss of MYR4.49m. DagangHalal has not had time to invest the funds it raised, there was MYR14.9m in the bank at the end of June 2016, so this should help revenues to grow to offset he higher overheads. Management was also distracted by the flotation in the first half. The company has developed a global e-marketplace and two more certification bodies have signed up for the Halal verification engine, taking the total to 40, and two say that they will sign up for the Halal certificate management system, which has eight users. The number of merchants using the system has also increased.

In the six months to June 2016, WMC Retail Partners (WELL) reduced its loss helped by the release of £42,000 of past provisions. Revenues dipped from £2.15m to £2.05m but the loss fell from £226,000 to £78,000. No interim dividend has been declared. Management expects to make an announcement about loss-making Cornish Market World in the near future.

Diversified Oil & Gas (DOIL) has almost trebled its first half revenues from $2.9m to $7.6m. One-off books gains meant that the reported pre-tax profit was $36.5m but in reality there was an underlying loss. There was a $381,000 cash outflow from operations. The company continues to make acquisitions.

Mechan Controls (MECP) is holding a general meeting to gain shareholder approval to buy back up to 200,000 shares – equivalent to 10% of the shares in issue. This is part of the board’s plan to enable shareholders to realise part of their investment following the termination of bid talk earlier in the year.

Ecovista (EVTP) says that planning permission has been granted by East Herts Council for 100 Rye Street.The building will be demolished and a six bedroom home will be built on the site. In the six months to June 2016, the loss increased from £92,000 to £168,000. Ecovista is seeking additional finance in order to acquire the 85% of Cingella Srl it does not already own. The company has until the end of 2017 to pay €4m for this stake. Ecovista’s interim loss increased from £36,000 to £168,000.

AIM

Conference call technology and services provider LoopUp (LOOP) has reported its interims one month after joining AIM. In the six months to June 2016, revenues grew from £4.81m to £6.38m. That includes revenues from a BT contract which is almost at an end and underlying growth was 38%. There was a pre-tax profit of £72,000, compared with a £619,000 loss. The cash raised in the flotation and the conversion of debt into shares means that pro forma net cash is £3.16m.The US is the biggest generator of revenues with the UK not far behind. The cash will be invested in further development spending and marketing. Non-executive chairman Lady Judge bought 15,754 shares at 126p each, compared with the flotation price of 100p. This is her total shareholding.

Gold recovery firm Goldplat (GDP) moved back into profit in the year to June 2016 as the performance of the gold recovery activities in South Africa and Ghana improved with more to come from capital investment in these operations. Revenues grew from £16.6m to £20.2m with a loss of £796,000 turning into a profit of £1.94m. Strong cash generation meant that there was net cash of £2.06m. There was a 23% increase in gold production, which included a toll processing contract with Rand Refinery. In contrast to the growth in output from the recovery operations, there was less produced by the Kilimapesa mine in Kenya . A new processing plant should come into action by the end of this year which will increase capacity; at Kilimepesa. There is scope to expand recovered gold production by sourcing material from South America.

Training systems supplier Pennant International (PEN) returned to profit in the first half of 2016 even though a number of major orders have not yet made a significant contribution. Revenues grew from £5.78m to £6.65m, while a loss of £755,000 was turned into a profit of £11,000. Four new contracts have been secured, including one with new client Lockheed Martin. Net cash was £2.6m at the end of the period, with £3.56m raised at 55p a share since June, but there is no dividend. The order book is worth £46m. There are tax losses of £4.7m so there should be no significant tax charge for up to three years depending on how fast profitability improves. A full year profit of £2.2m is forecast. Management wants to supplement organic growth with acquisitions, which are most likely to be in the core defence sector.

Shares in Sareum (SAR) doubled on the back of a licence agreement for its Chk1 inhibitor CCT245737 with ProNAi Therapeutics. Sareum and co-investment partner CRT Pioneer Fund will receive an initial payment of $7m with up to $2m payable on the successful transfer of two ongoing phase I clinical trials for the cancer drug. Sareum will receive 27.5% of these payments and it will have £300,000 of funding commitment returned. There could be additional payments totalling up to $319.5m depending on the achievement of milestones. There could be low single digit or high double digit royalties on a commercial product.

Savannah Resources (SAV) has raised £1.42m at 3.5p a share and directors and related investors have agreed to provide a further £830,000 at the same share price. The rest of the cash will come in after the closed period has ended. The funds will be used to develop copper projects in Oman and finance other projects in Mozambique and Finland. Joint venture partner Rio Tinto has extended the long stop date for the agreement over the combined Mutamba/Jangamo project in Mozambique until 10 October or a later agreed date. The interim loss was reduced from £1m to £800,000.

Premier African Minerals (PREM) made an increased interim loss because of operational issues at the RHA tungsten mine. The plant has been upgraded so these problems should be at an end and processing rates should improve. A further expansion to 16,000t a year is planned for next year and that investment could have an impact on production levels. Net debt was $3.8m at the end of June 2016.

Thor Mining (THR) is awaiting confirmation of assay results for its Molyhill tungsten project in Australia. The initial indications are that there is anomalous tungsten. Thor may start more closely spaced drilling after the results are received. A £1m impairment on the disposal of the Spring Hill project in February meant that the interim loss before tax increased from £880,000 to £1.75m. The initial proceeds of the disposal helped to reduce net debt to £445,000.

ValiRx (VAL) is on course to start dosing patients with lung cancer with its VAL401 treatment in the phase IIb trial. Higher R&D spending meant that the interim loss increased from £1.37m to £2.12m. There was £569,000 left in the bank at the end of June 2016 and since then £1.2m has been raised and a convertible loan facility of up to $3.75m has been agreed with Yorkville.

Cloud services provider Nasstar (NASA) increased its monthy recurring revenues to £1.23m even before the recent acquisition of Modrus which took the figure to £1.7m. In the first half of 2016, revenues were 14% higher at £8.1m. Underlying pre-tax profit improved from £860,000 to £981,000. Pro forma net debt is £3.5m and cash flow should be strong enough to wipe this out by the end of 2017. Full year profit is expected to rise from £1.6m to £2m. The benefits of the Modrus acquisition should help the profit to rise to £3.5m in 2017.

Digital audio visual agency MediaZest (MDZ) has won £250,000 of contracts in the past six weeks. The company has also said that the previously announced project with Rockar is for Jaguar Land Rover at Westfield Stratford.

MAIN MARKET

Standard list shell Auctus Growth (AUCT) is still seeking an acquisition and it has just over £1m left in the bank. The directors’ are not taking any salaries yet and costs are running at £35,000 a year.

Andrew Hore

 

Daily Actions – UK Main & AIM markets 24032016

IntellisysLogoDaily Actions is a daily summary analysis of changes in short term actions from our Daily Recs – AIM and Daily Recs Main markets reports. This report is typically distributed before the open of trading in London

AIM Market

ST Rec. changed
From To
Basic Resources    
Ariana Resources Neutral Buy
Tertiary Minerals Buy Neutral
Zincox Resources Neutral Buy
Financial Services    
Advanced Oncotherapy Buy Neutral
Health Care    
Sareum Holdings Neutral Buy
Industrial Good & Services    
Dart Group Neutral Sell
LPA Group Neutral Sell
Tricorn Group Sell Neutral
Oil & Gas – Explorers    
Petrel Resources Neutral Buy
Technology    
Brady Sell Neutral
Sopheon Neutral Buy

Main Market

ST Rec. changed
From To
Aerospace & Defence
Cobham Buy Neutral
Banks    
HSBC Buy Neutral
Royal Bank of Scotland Neutral Buy
Chemicals    
Synthomer Neutral Sell
House Construction    
Persimmon Neutral Sell
General Retail    
Kingfisher Neutral Sell
Media & Entertainment    
Johnston Press Neutral Buy
Trinity Mirror Neutral Buy
WPP Neutral Sell
Mining    
Randgold Resources Neutral Sell
Support Services    
Rentokil Initial Neutral Sell

 

 

RISK WARNING

Intellisys Intelligent Analysis Limited (‘Intellisys’) does not make personal recommendations. The information in this publication is provided solely to enable you to make your own investment decisions. If you are unsure about dealing in shares and other equity investments, you must contact your financial adviser as these types of investments may not be suitable for everyone. The value of stocks and shares, and the income from them, can fall as well as rise and you may not get back the full amount you originally invested. If denominated in a foreign currency, fluctuations in the exchange rate will also affect the value of stocks and shares and the income from them. Past performance is not necessarily a guide to future performance. You agree to abide fully with Intellisys’ Term & Conditions, which are available to www.intellisys.uk.com

 

The full reports are available from Intellisys Intelligent Analysis website (www.intellisys.uk.com) by clicking on the ‘Research’ tab.

 

 

DISCLAIMER: Intellisys Intelligent Analysis Limited has prepared this report. Intellisys (“Intellisys”) is the trading name of Intellisys Intelligent Analysis Limited. Intellisys Intelligent Analysis Limited is a provider of financial research reports that indicate the possible value of quoted company shares. The information contained within any and all of Intellisys’ reports are designed to present an objective assessment of the possible value or relative value of a company and/or an actuarial sector or stock market index. Intellisys utilises as extensive as possible range of valuation tools and proprietary systems to derive its outputs. The base data for the models are derived from sources believed to be accurate but Intellisys Intelligent Analysis Limited does not warrant or guarantee the accuracy or reliability of the source data or its models and proprietary systems. Subscribers, and casual readers, should not rely upon the Intellisys’ research outputs when forming specific investment decisions but should seek advice specific to their situation and investment requirements from a person authorised under the Financial Services and Markets Act 2000, before entering into any investment agreement.

Intellisys Intelligent Analysis Limited has used reasonable care and skill in compiling the content of this report. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness or accuracy of the information and no responsibility or liability is accepted to the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. In no event will Intellisys Intelligent Analysis Limited, Intellisys or any of its officers, employees or agents be liable to any other party for any direct, indirect, special or other consequential damages arising from the use of this report.

The Intellisys Intelligent Analysis Limited and/or Intellisys reports are not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the publication or availability of the Intellisys Intelligent Analysis Limited and/or Intellisys information may be prohibited. Persons in respect of whom such prohibitions apply must not access the Intellisys Intelligent Analysis Limited and/or Intellisys reports. Neither this document, nor any copy in whatever form of media, may be taken or transmitted into the United States, Canada, Australia, Ireland, South Africa or Japan or into any jurisdiction where it would be unlawful to do so. Any failure to comply with this restriction may constitute a violation of relevant local securities laws. Recipients of Intellisys Intelligent Analysis Limited and/or Intellisys reports outside the UK are not covered by the rules and regulations made for the protection of investors in the UK.

Any user distributing information taken from any Intellisys Intelligent Analysis Limited or Intellisys report and/or the Intellisys website, in whatever form, to any other person, agrees to attach a copy of this Disclaimer and the Terms and Conditions of Use pages and obtain the agreement of such other person to comply with the terms set forth.

Intellisys’ published reports are published for information purposes and only available to market counterparties, high net-worth and sophisticated individual investors.

No Intellisys report constitutes an offer or invitation to trade, sell, purchase or acquire any shares or other financial instruments in any company or any interest therein, nor shall it form the basis of any contract entered into for the sale of shares or any other financial instrument in any company.

Intellisys Intelligent Analysis Limited believes that the information within each and any of its reports to be correct, but its accuracy or completeness cannot be guaranteed. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or mis-statements, negligent or otherwise.

Intellisys Intelligent Analysis Limited (including its Directors, employees and representatives) or a connected person may have positions in or options or other financial instruments on any of the securities mentioned within a report, and may buy, sell or offer to purchase or sell such securities from time to time, subject to restrictions imposed by internal rules.

Subscribers, and casual reader, are reminded that the value of any financial instrument may go up or down and that past performance is not necessarily a guide to future performance.

Intellisys Intelligent Analysis Limited is not registered with or regulated by any financial regulatory authority and does not offer, provide or purport to provide or offer investment advice. Intellisys Intelligent Analysis Limited can be contacted at Woodfield Cottage, The Street, Mortimer, Berkshire, United Kingdom RG7 3DW.

 

Daily Actions – UK Main & AIM markets 17032016

IntellisysLogoDaily Actions is a daily summary analysis of changes in short term actions from our Daily Recs – AIM and Daily Recs Main markets reports. This report is typically distributed before the open of trading in London

AIM Market

ST Rec. changed
From To
Basic Resources    
Jubilee Platinum Neutral Buy
Landore Resources Buy Neutral
Mariana Resources Neutral Buy
Zincox Resources Neutral Buy
Financial Services    
ADVFN Buy Strong Buy
Dolphin Capital Investors Buy Strong Buy
EKF Diagnostics Holdings Neutral Buy
LMS Capital Neutral Buy
Polo Resources Neutral Buy
Trading Emissions Buy Neutral
Health Care    
AorTech International Neutral Buy
Sareum Holdings Neutral Buy
Verona Pharma Neutral Buy
Industrial Good & Services    
Accsys Technologies Buy Neutral
Oil & Gas – Producers    
Northern Petroleum Neutral Buy
Pantheon Resources Neutral Buy
Retail    
Stanley Gibbons Group Neutral Buy
Technology    
IS Solutions Sell Neutral
Travel & Leisure    
PPHE Hotel Group Sell Neutral

Main Market

ST Rec. changed
From To
Insurance    
Novae Group Neutral Sell
Leisure & Hotels    
Mitchells & Butlers Buy Neutral
Real Estate – REIS    
Capital & Regional Neutral Sell
Support Services    
Berendsen Neutral Sell

RISK WARNING

Intellisys Intelligent Analysis Limited (‘Intellisys’) does not make personal recommendations. The information in this publication is provided solely to enable you to make your own investment decisions. If you are unsure about dealing in shares and other equity investments, you must contact your financial adviser as these types of investments may not be suitable for everyone. The value of stocks and shares, and the income from them, can fall as well as rise and you may not get back the full amount you originally invested. If denominated in a foreign currency, fluctuations in the exchange rate will also affect the value of stocks and shares and the income from them. Past performance is not necessarily a guide to future performance. You agree to abide fully with Intellisys’ Term & Conditions, which are available to www.intellisys.uk.com

 

The full reports are available from Intellisys Intelligent Analysis website (www.intellisys.uk.com) by clicking on the ‘Research’ tab.

 

 

DISCLAIMER: Intellisys Intelligent Analysis Limited has prepared this report. Intellisys (“Intellisys”) is the trading name of Intellisys Intelligent Analysis Limited. Intellisys Intelligent Analysis Limited is a provider of financial research reports that indicate the possible value of quoted company shares. The information contained within any and all of Intellisys’ reports are designed to present an objective assessment of the possible value or relative value of a company and/or an actuarial sector or stock market index. Intellisys utilises as extensive as possible range of valuation tools and proprietary systems to derive its outputs. The base data for the models are derived from sources believed to be accurate but Intellisys Intelligent Analysis Limited does not warrant or guarantee the accuracy or reliability of the source data or its models and proprietary systems. Subscribers, and casual readers, should not rely upon the Intellisys’ research outputs when forming specific investment decisions but should seek advice specific to their situation and investment requirements from a person authorised under the Financial Services and Markets Act 2000, before entering into any investment agreement.

Intellisys Intelligent Analysis Limited has used reasonable care and skill in compiling the content of this report. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness or accuracy of the information and no responsibility or liability is accepted to the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. In no event will Intellisys Intelligent Analysis Limited, Intellisys or any of its officers, employees or agents be liable to any other party for any direct, indirect, special or other consequential damages arising from the use of this report.

The Intellisys Intelligent Analysis Limited and/or Intellisys reports are not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the publication or availability of the Intellisys Intelligent Analysis Limited and/or Intellisys information may be prohibited. Persons in respect of whom such prohibitions apply must not access the Intellisys Intelligent Analysis Limited and/or Intellisys reports. Neither this document, nor any copy in whatever form of media, may be taken or transmitted into the United States, Canada, Australia, Ireland, South Africa or Japan or into any jurisdiction where it would be unlawful to do so. Any failure to comply with this restriction may constitute a violation of relevant local securities laws. Recipients of Intellisys Intelligent Analysis Limited and/or Intellisys reports outside the UK are not covered by the rules and regulations made for the protection of investors in the UK.

Any user distributing information taken from any Intellisys Intelligent Analysis Limited or Intellisys report and/or the Intellisys website, in whatever form, to any other person, agrees to attach a copy of this Disclaimer and the Terms and Conditions of Use pages and obtain the agreement of such other person to comply with the terms set forth.

Intellisys’ published reports are published for information purposes and only available to market counterparties, high net-worth and sophisticated individual investors.

No Intellisys report constitutes an offer or invitation to trade, sell, purchase or acquire any shares or other financial instruments in any company or any interest therein, nor shall it form the basis of any contract entered into for the sale of shares or any other financial instrument in any company.

Intellisys Intelligent Analysis Limited believes that the information within each and any of its reports to be correct, but its accuracy or completeness cannot be guaranteed. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or mis-statements, negligent or otherwise.

Intellisys Intelligent Analysis Limited (including its Directors, employees and representatives) or a connected person may have positions in or options or other financial instruments on any of the securities mentioned within a report, and may buy, sell or offer to purchase or sell such securities from time to time, subject to restrictions imposed by internal rules.

Subscribers, and casual reader, are reminded that the value of any financial instrument may go up or down and that past performance is not necessarily a guide to future performance.

Intellisys Intelligent Analysis Limited is not registered with or regulated by any financial regulatory authority and does not offer, provide or purport to provide or offer investment advice. Intellisys Intelligent Analysis Limited can be contacted at Woodfield Cottage, The Street, Mortimer, Berkshire, United Kingdom RG7 3DW.

 

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.